Pulmonary Pharmacology · Module 1 of 7

Bronchodilators: Beta-2 Agonists and Anticholinergics

Airway smooth muscle signaling · SABAs and LABAs · SAMAs and LAMAs · Clinical positioning in asthma and COPD

Airway smooth muscle tone is governed by two opposing signaling axes: the Gq/IP3/calcium pathway (M3 muscarinic, CysLT1, H1 receptors) drives bronchoconstriction via myosin light chain kinase activation; the Gs/cyclic AMP/protein kinase A pathway (beta-2 adrenergic receptors) drives bronchodilation by inhibiting myosin light chain kinase and activating myosin light chain phosphatase. Phosphodiesterase 3 degrades cyclic AMP in airway smooth muscle; phosphodiesterase 4 in inflammatory cells — their inhibition prolongs bronchodilation or reduces inflammation, respectively.
Albuterol is the prototype short-acting beta-2 agonist (SABA): onset 5–15 minutes, duration 4–6 hours, ~200-fold beta-2 selectivity at therapeutic doses. Systemic adverse effects include skeletal muscle tremor (most common), tachycardia (direct beta-1 and reflex from vasodilation), hypokalemia (Na⁺/K⁺-ATPase upregulation in skeletal muscle — additive with corticosteroids and diuretics), and hyperglycemia. Levalbuterol is the isolated R-enantiomer; clinical trials have not shown a consistent advantage over equivalent doses of racemic albuterol.
LABAs differ critically: salmeterol is a partial agonist with slow onset (10–20 min) and 12-hour duration — not suitable for rescue use. Formoterol is a full agonist with rapid onset (1–3 min) and 12-hour duration, making it the only LABA usable as a rescue bronchodilator and the basis for SMART therapy. Indacaterol is an ultra-LABA with once-daily dosing for COPD. LABA monotherapy is absolutely contraindicated in asthma (SMART trial: excess asthma deaths without concurrent ICS); LABAs are used only in fixed-dose ICS/LABA combinations in asthma.
Anticholinergic bronchodilators block muscarinic receptors on airway smooth muscle and submucosal glands. Ipratropium (SAMA) is a quaternary ammonium compound with minimal systemic absorption, non-selective M1/M2/M3 blockade, onset 15–30 minutes, duration 4–8 hours; added to albuterol in acute severe asthma it reduces hospital admission rates ~25%. Tiotropium (LAMA) achieves functional M3 selectivity through kinetic dissociation: slow M3 dissociation (t½ ~35 h) versus fast M2 dissociation (t½ ~3.6 h), producing sustained once-daily bronchodilation while allowing M2 autoreceptor feedback to recover. Class adverse effects: dry mouth, urinary retention (BPH risk), constipation; absolute contraindication: angle-closure glaucoma.
Clinical positioning: GINA 2024 places as-needed budesonide/formoterol as the preferred reliever at all asthma steps — replacing as-needed SABA alone at steps 1 and 2. GOLD 2024 positions LABA/LAMA dual bronchodilation as first-line maintenance for moderate-to-severe COPD; triple therapy (ICS/LABA/LAMA) is reserved for high exacerbation risk with eosinophils ≥300 cells/µL. Acute severe asthma management: high-dose nebulized albuterol + ipratropium (additive, independent mechanisms) + systemic corticosteroids (anti-inflammatory, onset 4–6 hours); IV magnesium sulfate blocks calcium entry for bronchodilation independent of beta-2 and muscarinic pathways in refractory cases.

BPH = benign prostatic hyperplasia · cAMP = cyclic adenosine monophosphate · COPD = chronic obstructive pulmonary disease · CysLT1 = cysteinyl leukotriene receptor 1 · GINA = Global Initiative for Asthma · GOLD = Global Initiative for Chronic Obstructive Lung Disease · ICS = inhaled corticosteroid · IP3 = inositol trisphosphate · LABA = long-acting beta-2 agonist · LAMA = long-acting muscarinic antagonist · MDI = metered-dose inhaler · MLCK = myosin light chain kinase · PKA = protein kinase A · SABA = short-acting beta-2 agonist · SAMA = short-acting muscarinic antagonist · SMART = Single Maintenance and Reliever Therapy

Airway Smooth Muscle Signaling

Bronchoconstriction — Gq Pathway

Agonists: acetylcholine (M3), leukotrienes (CysLT1), histamine (H1) bind Gq-coupled receptors

Gq → phospholipase C → IP3 + diacylglycerol

IP3 releases Ca²⁺ from sarcoplasmic reticulum → Ca²⁺-calmodulin complex

Ca²⁺-calmodulin activates MLCK → myosin phosphorylation → contraction

⇄

Bronchodilation — Gs/cAMP Pathway

Beta-2 agonists activate Gs-coupled beta-2 adrenergic receptors on airway smooth muscle

Gs → adenylyl cyclase → cyclic AMP ↑

cAMP activates PKA → MLCK inhibited + myosin light chain phosphatase activated

Myosin dephosphorylation → cross-bridge dissociation → relaxation

M1 — Ganglionic

Facilitates Parasympathetic Tone

Located on parasympathetic ganglia in airway
Amplifies ganglionic neurotransmission → increases overall parasympathetic drive
Blocking M1 reduces parasympathetic amplification (one benefit of ipratropium)

M3 — Effector

Primary Bronchoconstriction Target

On airway smooth muscle and submucosal glands
Gq-coupled: drives IP3 → Ca²⁺ → MLCK → contraction + mucus secretion
Primary therapeutic target of all anticholinergic bronchodilators
Blocking M3 = bronchoconstriction relief + reduced mucus hypersecretion

M2 — Autoreceptor

Inhibitory Feedback Brake

On postganglionic nerve terminals — presynaptic autoreceptor
Acetylcholine binding M2 → inhibits further release (negative feedback)
Blocking M2 removes the brake → increased ACh release partially offsets M3 blockade
Ideal LAMA: block M1 + M3, spare M2 → tiotropium achieves this kinetically

Beta-2 Agonist Comparison

	Albuterol	Salmeterol	Formoterol	Indacaterol
Class	SABA	LABA	LABA	Ultra-LABA
Onset	5–15 min	10–20 min	1–3 min	<5 min
Duration	4–6 h	12 h	12 h	24 h
Intrinsic efficacy	Full agonist	Partial agonist	Full agonist	Full agonist
Rescue use?	Yes — first-line	No — too slow	Yes — SMART only	No — COPD only
Primary use	Rescue; pre-exercise	Asthma/COPD maintenance (ICS/LABA only in asthma)	SMART therapy; COPD maintenance	COPD once-daily maintenance

SABA Adverse Effects

Systemic Beta-2 Effects of Albuterol

Skeletal muscle tremor — most common; beta-2 activation in slow-twitch fibers; dose-dependent
Tachycardia — direct cardiac beta-1 stimulation + reflex from peripheral vasodilation
Hypokalemia — Na⁺/K⁺-ATPase upregulation drives K⁺ into cells; additive with corticosteroids and diuretics in acute asthma
Hyperglycemia — glycogenolysis + inhibition of insulin secretion from pancreatic beta cells

SMART Therapy

Budesonide/Formoterol as Maintenance and Reliever

Single inhaler serves as both daily controller and as-needed reliever
Possible only with formoterol — its rapid onset (1–3 min) allows rescue use
GINA 2024: preferred reliever at all steps, replacing as-needed SABA alone at steps 1 and 2
Reduces severe exacerbation rates versus as-needed SABA; lower total ICS exposure in infrequent users
ICS component always present — never a LABA alone in asthma

Anticholinergic Bronchodilators

SAMA

Ipratropium

Quaternary ammonium derivative of atropine — permanent positive charge prevents systemic absorption; minimal CNS effects
Non-selective: blocks M1, M2, and M3 without subtype preference
Onset 15–30 min | Duration 4–8 h
Add-on in acute severe asthma: independent pathway from beta-2 agonists → additive bronchodilation; reduces hospital admissions ~25%
Standard acute dosing: nebulized 0.5 mg with albuterol 2.5–5 mg every 20 min ×3

LAMA

Tiotropium

Kinetic M3 selectivity: dissociates slowly from M3 (t½ ~35 h) but rapidly from M2 (t½ ~3.6 h)
Once-daily dosing maintains M3 blockade throughout 24 h while M2 autoreceptor feedback recovers between doses
First-line COPD maintenance; superior sustained bronchodilation versus ipratropium
Other LAMAs: umeclidinium, aclidinium, glycopyrrolate — once- or twice-daily options
Absolute contraindication: angle-closure glaucoma (especially nebulized; drug reaching eye precipitates acute closure)

Anticholinergic AEs

Class Adverse Effects

Dry mouth — most common; up to 16% on tiotropium
Urinary retention — reduced detrusor parasympathetic tone; significant risk in BPH
Constipation — reduced GI parasympathetic tone
Acute angle-closure glaucoma — absolute contraindication; nebulized formulations highest risk

GOLD 2024

COPD Bronchodilator Positioning

Moderate-to-severe COPD: LABA/LAMA dual bronchodilation — first-line maintenance
Triple therapy (ICS/LABA/LAMA): high exacerbation risk + eosinophils ≥300 cells/µL
SABA for acute symptom relief in all groups
LABA monotherapy appropriate in COPD (SMART trial asthma restriction does not apply)

Inhaler Devices

Delivery Principles

Optimal deposition: 1–5 µm aerodynamic diameter; larger particles deposit in oropharynx
MDI requires coordinated actuation + inhalation; spacer eliminates this requirement and improves lower airway deposition
ICS via MDI: spacer reduces oropharyngeal deposition → less candidiasis/dysphonia
Dry powder inhalers require minimum inspiratory flow — unreliable in severe obstruction

Acute Severe Asthma and Safety Rules

Acute Severe Asthma

Step-Wise Management

High-dose nebulized albuterol — immediate first-line bronchodilator; repeat every 20 min ×3
Add ipratropium — independent muscarinic pathway; additive bronchodilation; reduces admissions ~25%
Systemic corticosteroids — oral prednisone or IV methylprednisolone; anti-inflammatory onset 4–6 h; not acutely bronchodilating
IV magnesium sulfate — refractory to initial therapy; blocks Ca²⁺ entry into smooth muscle; bronchodilation independent of beta-2 and muscarinic pathways
Monitor: serum K⁺ (hypokalemia additive with corticosteroids/diuretics), cardiac rhythm, glucose

PDE Inhibitors

Phosphodiesterase Pharmacology

PDE3 — principal cAMP-degrading isoform in airway smooth muscle; PDE3 inhibition prolongs bronchodilation
PDE4 — dominant isoform in inflammatory cells (eosinophils, mast cells, neutrophils, macrophages)
Roflumilast — selective PDE4 inhibitor; used in COPD for anti-inflammatory effect (reduces exacerbations), not as primary bronchodilator
Theophylline — non-selective PDE inhibitor (PDE3 + PDE4); narrow therapeutic index; largely replaced by inhaled therapy

LABA Safety Rule — Absolute Contraindication in Asthma

LABA monotherapy is absolutely contraindicated in asthma at every step and every severity. The SMART trial (Salmeterol Multicenter Asthma Research Trial) was terminated early for a statistically significant increase in asthma-related deaths in the salmeterol arm, concentrated in patients not using concurrent inhaled corticosteroids. The proposed mechanism: LABAs suppress symptoms and bronchospasm without controlling the underlying eosinophilic inflammation, allowing silent disease progression to fatal exacerbation.

As a consequence, LABAs in asthma are approved only as fixed-dose ICS/LABA combinations. A separate LABA inhaler is never prescribed without a concurrent ICS inhaler. Subsequent trials (AUSTRI, STADIA, VESTRI) confirmed the excess mortality signal is abolished when LABAs are co-administered with ICS. This constraint does not apply in COPD — LABA monotherapy and LABA/LAMA combinations are appropriate in COPD, where the SMART trial's asthma-based safety finding has not been replicated.

Clinical Framework — Bronchodilator Positioning by Disease

Asthma (GINA 2024): as-needed budesonide/formoterol is the preferred reliever at all steps — ICS component always present. LABA only in fixed ICS/LABA combination. Acute severe asthma: albuterol + ipratropium + systemic corticosteroids; add IV magnesium for inadequate response.

COPD (GOLD 2024): LABA/LAMA dual bronchodilation for moderate-to-severe disease; triple therapy (ICS/LABA/LAMA) for high exacerbation risk with eosinophils ≥300/µL; SABA for acute relief. Roflumilast adds anti-inflammatory benefit via PDE4 inhibition in selected patients. LABA monotherapy appropriate.

Suggested References

Author / Source	Title	Publication
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed.	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill, 2023
Barnes PJ	Cellular and molecular mechanisms of asthma and COPD	Clin Sci (Lond). 2017;131(13):1541–1558
Cazzola M, Page CP, Calzetta L, Matera MG	Pharmacology and therapeutics of bronchodilators	Pharmacol Rev. 2012;64(3):450–504
Barnes PJ	Nitric oxide and airway disease	Ann Med. 1995;27(3):389–393
Rodrigo GJ, Rodrigo C, Hall JB	Acute asthma in adults: a review	Chest. 2004;125(3):1081–1102
Schreck DM, Babin S	Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED	Am J Emerg Med. 2005;23(7):842–847
Busse WW, Bateman ED, Caplan AL, et al	Combined analysis of asthma safety trials of long-acting beta2-agonists	N Engl J Med. 2018;378(26):2497–2505
Rodrigo GJ, Castro-Rodriguez JA	Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis	Thorax. 2005;60(9):740–746
Wise RA, Anzueto A, Cotton D, et al	Tiotropium Respimat inhaler and the risk of death in COPD	N Engl J Med. 2013;369(16):1491–1501
Wedzicha JA, Banerji D, Chapman KR, et al	Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD	N Engl J Med. 2016;374(23):2222–2234
Dolovich MB, Dhand R	Aerosol drug delivery: developments in device design and clinical use	Lancet. 2011;377(9770):1032–1045
Agusti A, Celli BR, Criner GJ, et al	Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary	Eur Respir J. 2023;61(4):2300239
O'Byrne PM, FitzGerald JM, Bateman ED, et al	Inhaled combined budesonide-formoterol as needed in mild asthma	N Engl J Med. 2018;378(20):1865–1876